Stay updated with breaking news from Ian Flinn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
Investigators from the National Institutes of Health report 2 partial responses in 3 peripheral T-cell lymphoma patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma patients in ongoing...
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 P...
<p>A new targeted drug, studied by researchers at <a href="https://cancer.osu.edu/">The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)</a>, may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia and Non-Hodgkin lymphoma whose disease has stopped responding to standard treatments.</p>
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.